Published in

American Physiological Society, American Journal of Physiology - Heart and Circulatory Physiology, 1(325), p. H136-H141, 2023

DOI: 10.1152/ajpheart.00238.2023

Links

Tools

Export citation

Search in Google Scholar

Placenta-targeted treatment with nMitoQ prevents an endothelin receptor-A pathway cardiac phenotype observed in adult male offspring exposed to hypoxia in utero

Journal article published in 2023 by Nataliia Hula ORCID, Raven Kirschenman, Anita Quon ORCID, Floor Spaans, Tom J. Phillips ORCID, C. Patrick Case, Christy-Lynn M. Cooke, Sandra T. Davidge ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

In this follow-up study, we showed a complete lack of recovery from I/R injury after the application of an ETA receptor antagonist (ABT-627) in adult male offspring exposed to hypoxia in utero while maternal treatment with nMitoQ during prenatal hypoxia exposure prevented this effect. Our data suggest that nMitoQ treatment during hypoxic pregnancies may prevent a hypoxic cardiac phenotype in adult male offspring.